Your Cart Is Empty!
In the psoriasis market, brands are gaining or losing market share to the competition due to the effects of market barriers.
If barriers did not exist, the market landscape would be transformed, and several key brands would see their market share increase dramatically.
The report compares 6 major psoriasis treatments – Humira, Stelara, Enbrel, Remicade, Cosentyx, and Otezla.
You’ll get a detailed picture of what prevents doctors from prescribing your brand, who you’re losing market share to, and who you’re taking it from.
That’s information you can use to win back lost share and compete more effectively.
Not your market? Click here to see the EU report
Get Answers to Key Questions about Psoriasis Drug Brands
Cosentyx (secukinumab; Novartis): Which two barriers are contributing to more than 50% of its net losses?
Enbrel (etanercept; Pfizer): Enbrel is currently prescribed by more than 90% of physicians, but what level is Enbrel's gain from market barriers in real terms?
Humira (adalimumab; AbbVie): Humira’s market dominance is being support by a market barrier, what would happen in a barrier free world?
Otezla (apremilast; Celgene): What percentage of physicians would consider Otezla, and what effect could enhancing communication with them have on market share?
Remicade (infliximab; Janssen Biotech): Remicade experiences roughly the same number of barriers as Humira, but which barriers are creating the huge disparity in prescription numbers?
Stelara (ustekinumab; Janssen Biotech): What effect is Stelara's pricing strategy having on its uptake, and which leading competitor is it taking market share from?
Prescriptions in the US are significantly affected by market barriers: see which ones are having the most effect.
Market dominated by three players: Due to the significant potential gains/losses, if competitors could remove/side-step barriers, we would see a near level playing field.
Even combined, the losing drugs hold minimal prescription usage: The percentage of the two least prescribed drugs added together is still less than 50% than that of any of the leading drugs.
Disparity between barriers and market share: Counter-intuitively, two of the drugs holding the lowest prescription numbers show the highest number of physicians that have zero barriers to prescribing.
Significant opportunities for the growth of weaker drugs: Tackling the most prominent market barriers could alleviate the gaps between themselves and the most prescribed drugs.
Market leader owes its strong lead to certain market barriers: A drug is taking much of its market share from its competitors, strongly securing its position as the most prescribed drug.
EU and US landscapes strikingly different: The US sees drugs being inhibited by market barriers circa 50% more when compared to the EU5. See the EU5 report to find out what the other key differences there are.
Exploring Market Access Issues
Market Access Impact: psoriasis explores key issues affecting dermatology drug manufacturers. You’ll learn:Exploring Market Access Issues
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 Medical Dermatologists in the US, chosen from the largest community of validated physicians in the world.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with melanoma in total in the last month
We conducted the survey between January 28th – February 11th, 2016.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
Table of Contents
1 What are market barriers?
2 About this report
3 About the survey
4 Brands included in the survey
5 Executive summary
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.